The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
01-Sep-17
$NA
Target:
B-G Mechanical Contractors, Inc., B-G Mechanical Services, Inc., Elmsford Sheet Metal Works, Inc., Fred Williams, Inc., H.T. Lyons, Inc. and TryState Mechanical, Inc.
Acquiror:
ENGIE North America
Advised Talen Energy, one of the largest independent energy and power producers in the United States, on the sale of six subsidiaries, within its Mechanical Services business, to Engie North America
24-Aug-17
$NA
Target:
Morris Corporation
Acquiror:
Sodexo SA
Advised Morris Corporation, a leading independent player in Australia’s remote facilities management sector, on its sale to Sodexo SA, a France-based leading global facilities services company
23-Aug-17
$NA
Target:
Thermamax
Acquiror:
Capvis Equity Partners
Advised the shareholders of Thermamax, a leading family-owned manufacturer of highly engineered high temperature insulation solutions on the sale of the Company
14-Jul-17
$775 million
Target:
Programmed Maintenance Services Limited
Acquiror:
PERSOL HOLDINGS CO LTD.
Advised PERSOL HOLDINGS, one of Japan’s largest HR service companies, on its acquisition of ASX-listed Programmed Maintenance Services, a leading Australian and New Zealand based provider of staffing and maintenance services
03-Apr-17
$205 million
Target:
Inenco Group Pty Ltd
Acquiror:
Genuine Parts Company
Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products
22-Feb-17
$533 million
Target:
Lion’s stake in Warrnambool Cheese and Butter Factory Company
Acquiror:
Saputo Inc.
Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer
03-Jan-17
$536 million
Target:
LCH.Clearnet SA
Acquiror:
Euronext N.V.
Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated
24-Nov-16
$NA
Target:
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Rivopharm SA
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
23-Nov-16
$NA
Target:
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Acquiror:
Arrow Generiques SAS
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
14-Nov-16
$346 million
Target:
Etrion Corporation's Italian solar photovoltaic platform
Acquiror:
Ultor S.p.A.
Advised Etrion Corporation, a solar independent power producer and developer, on the sale of its 60MW Italian solar photovoltaic platform to Ultor S.p.A. (a joint venture owned equally by Enel Green Power S.p.A. and F2i Fondi Italiani per le infrastrutture) for an Enterprise Value of €323mm
14-Nov-16
$NA
Target:
Lion’s Australian Premium Wine Business – Fine Wine Partners
Acquiror:
Accolade Wines
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity
03-Nov-16
$NA
Target:
Fragrance Resources Group
Acquiror:
International Flavors & Fragrances Inc.
Advised IFF, one of the world’s largest flavors and fragrances businesses, on the acquisition of Fragrance Resources Group, a family-owned fragrance company headquartered in Switzerland
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
18-Aug-16
$3.2 billion
Target:
Valves & Controls Business of Pentair
Acquiror:
Emerson
Advised Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
16-May-16
$874 million
Target:
Equinix Data Center Assets
Acquiror:
Digital Realty Trust
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
10-May-16
$NA
Target:
Brasil/CT
Acquiror:
Invest Tech
Advised Brasil/CT on a capital injection made by Invest Tech in the Company. Brasil/CT specializes in the e-commerce market and is a leader in B2C and B2B full-commerce and loyalty operations in Brazil. Invest Tech is an investment manager focused on venture capital and private equity in the technology and telecom sectors
04-May-16
$NA
Target:
Affinia Group
Acquiror:
MANN+HUMMEL GmbH
Advised MANN+HUMMEL GmbH, a leading global manufacturer of filtration solutions, on the acquisition of the global filtration operations (excluding the Affinia South America operations) of Affinia Group